Related Experiment Video
Updated: May 16, 2026
05:38
Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model
Published on: January 7, 2019
Methylphenidate : a treatment for Parkinson's disease?
David Devos1, Caroline Moreau, Arnaud Delval
1Department of Medical Pharmacology, EA 1046, Lille Nord de France University, CHU Lille, Lille, France. david.devos@chru-lille.fr
CNS Drugs
|November 20, 2012
Summary
Methylphenidate shows promise for treating non-motor symptoms and gait issues like freezing of gait in Parkinson's disease (PD). Further research, including randomized controlled trials, is needed to confirm its effectiveness and optimize its use alongside dopaminergic treatments.
Area of Science:
- Neuroscience
- Pharmacology
- Movement Disorders
Background:
- Parkinson's disease (PD) is a neurodegenerative disorder affecting motor and non-motor functions.
- Current PD treatments focus on dopamine replacement but do not target the dopamine transporter (DaT).
- Non-motor symptoms and gait disturbances like freezing of gait (FoG) significantly impact PD patient quality of life.
Purpose of the Study:
- To review the effects of methylphenidate on severe gait disorders and non-motor symptoms in advanced Parkinson's disease.
- To discuss the potential of methylphenidate, a DaT inhibitor, in PD treatment.
- To highlight the need for further rigorous clinical trials.
Main Methods:
- Review of open-label studies and randomized controlled trials on methylphenidate in PD.
- Analysis of methylphenidate's pharmacodynamic effects on dopamine and norepinephrine transporters.
- Discussion of clinical outcomes related to gait and non-motor symptoms.
Main Results:
- Methylphenidate's inhibition of DaT suggests potential therapeutic value in PD.
- Preliminary studies indicate possible benefits for severe gait disorders and non-motor symptoms.
- The influence of concomitant dopaminergic therapies on methylphenidate's efficacy requires careful consideration.
Conclusions:
- Methylphenidate may offer a novel therapeutic avenue for specific PD symptoms.
- A significant lack of high-quality randomized controlled trials currently limits definitive conclusions.
- Optimizing methylphenidate treatment requires careful patient selection and consideration of dopaminergic medication interactions. Pharmacogenetics may aid in personalized treatment strategies.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...